Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $75,622 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $8,121 | $6,222 | $0 | $0 |
| Gross Profit | $67,501 | -$6,222 | $0 | $0 |
| % Margin | 89.3% | – | – | – |
| R&D Expenses | $121,563 | $105,050 | $85,061 | $57,155 |
| G&A Expenses | $35,171 | $32,039 | $27,323 | $15,727 |
| SG&A Expenses | $35,171 | $32,039 | $27,323 | $15,727 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$8,121 | $0 | $0 | $0 |
| Operating Expenses | $148,613 | $137,089 | $112,384 | $72,882 |
| Operating Income | -$81,112 | -$143,311 | -$112,384 | -$72,882 |
| % Margin | -107.3% | – | – | – |
| Other Income/Exp. Net | $10,982 | $8,297 | $3,883 | -$1,076 |
| Pre-Tax Income | -$70,130 | -$135,014 | -$108,501 | -$73,958 |
| Tax Expense | $2,570 | $338 | $0 | $0 |
| Net Income | -$72,700 | -$135,352 | -$108,501 | -$73,958 |
| % Margin | -96.1% | – | – | – |
| EPS | -0.98 | -2.63 | -2.3 | -1.59 |
| % Growth | 62.7% | -14.3% | -44.7% | – |
| EPS Diluted | -0.98 | -2.63 | -2.3 | -1.59 |
| Weighted Avg Shares Out | 73,910 | 51,397 | 47,227 | 46,536 |
| Weighted Avg Shares Out Dil | 73,910 | 51,397 | 47,227 | 46,536 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,566 | $9,334 | $3,764 | $46 |
| Interest Expense | $0 | $0 | $3,764 | $0 |
| Depreciation & Amortization | $8,121 | $6,222 | $3,745 | $2,132 |
| EBITDA | -$72,991 | -$137,089 | -$108,639 | -$70,750 |
| % Margin | -96.5% | – | – | – |